These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 4210526)

  • 1. Pharmacodynamic and pharmacokinetic measurements of antitumor agents.
    Mellett LB
    Clin Pharmacol Ther; 1974 Jul; 16(1):230-42. PubMed ID: 4210526
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytosine arabinoside (NSC-63878)--clinical brochure.
    Livingston RB; Carter SK
    Cancer Chemother Rep 3; 1968 Dec; 1(1):179-205. PubMed ID: 4989814
    [No Abstract]   [Full Text] [Related]  

  • 3. The chemotherapy of human and animal acute leukemia.
    Goldin A; Sandberg JS; Henderson ES; Newman JW; Frei E; Holland JF
    Cancer Chemother Rep; 1971 Nov; 55(4):309-505. PubMed ID: 4945857
    [No Abstract]   [Full Text] [Related]  

  • 4. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy.
    Skipper HE; Perry S
    Cancer Res; 1970 Jun; 30(6):1883-97. PubMed ID: 4917694
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539
    [No Abstract]   [Full Text] [Related]  

  • 6. The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.
    Woodman RJ; Sirica AE; Gang M; Kline I; Venditti JM
    Chemotherapy; 1973; 18(3):169-83. PubMed ID: 4119363
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract]   [Full Text] [Related]  

  • 8. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.
    Skipper HE; Schabel FM; Mellett LB; Montgomery JA; Wilkoff LJ; Lloyd HH; Brockman RW
    Cancer Chemother Rep; 1970 Dec; 54(6):431-50. PubMed ID: 5527023
    [No Abstract]   [Full Text] [Related]  

  • 9. Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210.
    Straus MJ; Goldin A
    Cancer Chemother Rep; 1972 Feb; 56(1):19-23. PubMed ID: 5030804
    [No Abstract]   [Full Text] [Related]  

  • 10. Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo.
    Young RC; Goldberg D; Schein PS
    Biochem Pharmacol; 1973 Jan; 22(2):277-80. PubMed ID: 4763256
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of long-term human leukocyte cell cultures as models for the study of antileukemic agents.
    Hirshaut Y; Weiss GH; Perry S
    Cancer Res; 1969 Sep; 29(9):1732-40. PubMed ID: 5258874
    [No Abstract]   [Full Text] [Related]  

  • 12. Electronic volume analysis of L1210 chemotherapy.
    Zucker RM; Helfman D
    Cancer Res; 1976 Dec; 36(12):4434-8. PubMed ID: 1000492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collateral sensitivity of resistant lines of mouse leukemias L1210 and L5178Y.
    Schmid FA; Hutchison DJ
    Cancer Res; 1972 Apr; 32(4):808-12. PubMed ID: 5014791
    [No Abstract]   [Full Text] [Related]  

  • 14. Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia L1210.
    Avery TL; Roberts D
    Eur J Cancer (1965); 1974 Jul; 10(7):425-9. PubMed ID: 4457345
    [No Abstract]   [Full Text] [Related]  

  • 15. Biochemical and pharmacologic studies with 1- -D-arabinofuranosylcytosine 5'-adamantoate (NSC-117614), a depot form of cytarabine.
    Neil GL; Buskirk HH; Moxley TE; Manak RC; Kuentzel SL; Bhuyan BK
    Biochem Pharmacol; 1971 Dec; 20(12):3295-308. PubMed ID: 5002403
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.
    Ho DH; Frei E
    Clin Pharmacol Ther; 1971; 12(6):944-54. PubMed ID: 5289712
    [No Abstract]   [Full Text] [Related]  

  • 17. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
    Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
    [No Abstract]   [Full Text] [Related]  

  • 18. Antitumor activity of cyclocytidine in a variety of tumors.
    Hoshi A; Kanzawa F; Kuretani K
    Gan; 1972 Jun; 63(3):353-60. PubMed ID: 5072834
    [No Abstract]   [Full Text] [Related]  

  • 19. Biochemical aspects of drug combinations.
    Brockman RW
    Cancer Chemother Rep 2; 1974 Mar; 4(1):115-29. PubMed ID: 4135108
    [No Abstract]   [Full Text] [Related]  

  • 20. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.